La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia

Identifieur interne : 000270 ( France/Analysis ); précédent : 000269; suivant : 000271

Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia

Auteurs : Howard T. J. Mount [Canada] ; Jean-Claude Martel [France] ; Paul Fluit [Canada] ; YINGJI WU [Canada] ; Eleanor Gallo-Hendrikx [Canada] ; Cristina Cosi [France] ; Marc R. Marien [France]

Source :

RBID : Pascal:04-0345628

Descripteurs français

English descriptors

Abstract

Ataxia-telangiectasia (A-T) is a genetic disease, associated with progressive motor impairment and a lack of functional ATM protein. It has been reported that immunoreactive tyrosine hydroxylase and dopamine transporter are reduced in an Atm-/- mouse model of A-T. These observations led to a hypothesis that A-T is associated with loss of nigrostriatal dopamine and prompted the launch of clinical trials to evaluate a therapeutic utility of the anti-parkinsonian drug, L-DOPA. To test for dopamine depletion more directly, we measured regional levels of monoamines and their metabolites in the Atm-/-mouse brain. We also measured levels of NAD+, a cofactor for dopamine biosynthesis and substrate of the DNA damage surveillance enzyme, poly(ADP-ribose) polymerase (PARP). Constitutive activation of PARP has been posited to cause NAD+ depletion. We observed no reduction in monoamine transmitters and no depletion of NAD+, or other high energy phosphate donors in the adult Atm-/- cerebellum, striatum, or ventral mesencephalon. However, our studies did reveal a progressive sensorimotor impairment in Atm-/-mice that may serve as a relevant proxy for progressive neurological impairment in the human disease. Our results call into question the involvement of dopamine in A-T and the therapeutic strategy of enhancing dopaminergic function with L-DOPA.


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:04-0345628

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia</title>
<author>
<name sortKey="Mount, Howard T J" sort="Mount, Howard T J" uniqKey="Mount H" first="Howard T. J." last="Mount">Howard T. J. Mount</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="4">
<inist:fA14 i1="02">
<s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Martel, Jean Claude" sort="Martel, Jean Claude" uniqKey="Martel J" first="Jean-Claude" last="Martel">Jean-Claude Martel</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut de Reclterche Pierre Fabre</s1>
<s2>Castres</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Castres</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fluit, Paul" sort="Fluit, Paul" uniqKey="Fluit P" first="Paul" last="Fluit">Paul Fluit</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Yingji Wu" sort="Yingji Wu" uniqKey="Yingji Wu" last="Yingji Wu">YINGJI WU</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Gallo Hendrikx, Eleanor" sort="Gallo Hendrikx, Eleanor" uniqKey="Gallo Hendrikx E" first="Eleanor" last="Gallo-Hendrikx">Eleanor Gallo-Hendrikx</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Cosi, Cristina" sort="Cosi, Cristina" uniqKey="Cosi C" first="Cristina" last="Cosi">Cristina Cosi</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut de Reclterche Pierre Fabre</s1>
<s2>Castres</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Castres</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Marien, Marc R" sort="Marien, Marc R" uniqKey="Marien M" first="Marc R." last="Marien">Marc R. Marien</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut de Reclterche Pierre Fabre</s1>
<s2>Castres</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Castres</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">04-0345628</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0345628 INIST</idno>
<idno type="RBID">Pascal:04-0345628</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000994</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000329</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000850</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000850</idno>
<idno type="wicri:doubleKey">0022-3042:2004:Mount H:progressive:sensorimotor:impairment</idno>
<idno type="wicri:Area/Main/Merge">003072</idno>
<idno type="wicri:Area/Main/Curation">002D07</idno>
<idno type="wicri:Area/Main/Exploration">002D07</idno>
<idno type="wicri:Area/France/Extraction">000270</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia</title>
<author>
<name sortKey="Mount, Howard T J" sort="Mount, Howard T J" uniqKey="Mount H" first="Howard T. J." last="Mount">Howard T. J. Mount</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="4">
<inist:fA14 i1="02">
<s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Martel, Jean Claude" sort="Martel, Jean Claude" uniqKey="Martel J" first="Jean-Claude" last="Martel">Jean-Claude Martel</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut de Reclterche Pierre Fabre</s1>
<s2>Castres</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Castres</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fluit, Paul" sort="Fluit, Paul" uniqKey="Fluit P" first="Paul" last="Fluit">Paul Fluit</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Yingji Wu" sort="Yingji Wu" uniqKey="Yingji Wu" last="Yingji Wu">YINGJI WU</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Gallo Hendrikx, Eleanor" sort="Gallo Hendrikx, Eleanor" uniqKey="Gallo Hendrikx E" first="Eleanor" last="Gallo-Hendrikx">Eleanor Gallo-Hendrikx</name>
<affiliation wicri:level="4">
<inist:fA14 i1="01">
<s1>Centre for Research in Neurodegenerative Diseases, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Cosi, Cristina" sort="Cosi, Cristina" uniqKey="Cosi C" first="Cristina" last="Cosi">Cristina Cosi</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut de Reclterche Pierre Fabre</s1>
<s2>Castres</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Castres</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Marien, Marc R" sort="Marien, Marc R" uniqKey="Marien M" first="Marc R." last="Marien">Marc R. Marien</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut de Reclterche Pierre Fabre</s1>
<s2>Castres</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Castres</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of neurochemistry</title>
<title level="j" type="abbreviated">J. neurochem.</title>
<idno type="ISSN">0022-3042</idno>
<imprint>
<date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of neurochemistry</title>
<title level="j" type="abbreviated">J. neurochem.</title>
<idno type="ISSN">0022-3042</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animal</term>
<term>Ataxia telangiectasia</term>
<term>Biosynthesis</term>
<term>Cerebellum</term>
<term>Depletion</term>
<term>Dopamine</term>
<term>Mouse</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson disease</term>
<term>Posture</term>
<term>Sensorimotor coordination</term>
<term>Tyrosine 3-monooxygenase</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Dopamine</term>
<term>Déplétion</term>
<term>Biosynthèse</term>
<term>Voie nigrostriatale</term>
<term>Tyrosine 3-monooxygenase</term>
<term>Coordination sensorimotrice</term>
<term>Ataxie télangiectasie</term>
<term>Posture</term>
<term>Cervelet</term>
<term>Parkinson maladie</term>
<term>Souris</term>
<term>Animal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Ataxia-telangiectasia (A-T) is a genetic disease, associated with progressive motor impairment and a lack of functional ATM protein. It has been reported that immunoreactive tyrosine hydroxylase and dopamine transporter are reduced in an Atm
<sup>-/-</sup>
mouse model of A-T. These observations led to a hypothesis that A-T is associated with loss of nigrostriatal dopamine and prompted the launch of clinical trials to evaluate a therapeutic utility of the anti-parkinsonian drug, L-DOPA. To test for dopamine depletion more directly, we measured regional levels of monoamines and their metabolites in the Atm
<sup>-/-</sup>
mouse brain. We also measured levels of NAD
<sup>+</sup>
, a cofactor for dopamine biosynthesis and substrate of the DNA damage surveillance enzyme, poly(ADP-ribose) polymerase (PARP). Constitutive activation of PARP has been posited to cause NAD
<sup>+</sup>
depletion. We observed no reduction in monoamine transmitters and no depletion of NAD
<sup>+</sup>
, or other high energy phosphate donors in the adult Atm
<sup>-/-</sup>
cerebellum, striatum, or ventral mesencephalon. However, our studies did reveal a progressive sensorimotor impairment in Atm
<sup>-/-</sup>
mice that may serve as a relevant proxy for progressive neurological impairment in the human disease. Our results call into question the involvement of dopamine in A-T and the therapeutic strategy of enhancing dopaminergic function with L-DOPA.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
<li>France</li>
</country>
<region>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Ontario</li>
</region>
<settlement>
<li>Castres</li>
<li>Toronto</li>
</settlement>
<orgName>
<li>Université de Toronto</li>
</orgName>
</list>
<tree>
<country name="Canada">
<region name="Ontario">
<name sortKey="Mount, Howard T J" sort="Mount, Howard T J" uniqKey="Mount H" first="Howard T. J." last="Mount">Howard T. J. Mount</name>
</region>
<name sortKey="Fluit, Paul" sort="Fluit, Paul" uniqKey="Fluit P" first="Paul" last="Fluit">Paul Fluit</name>
<name sortKey="Gallo Hendrikx, Eleanor" sort="Gallo Hendrikx, Eleanor" uniqKey="Gallo Hendrikx E" first="Eleanor" last="Gallo-Hendrikx">Eleanor Gallo-Hendrikx</name>
<name sortKey="Mount, Howard T J" sort="Mount, Howard T J" uniqKey="Mount H" first="Howard T. J." last="Mount">Howard T. J. Mount</name>
<name sortKey="Yingji Wu" sort="Yingji Wu" uniqKey="Yingji Wu" last="Yingji Wu">YINGJI WU</name>
</country>
<country name="France">
<region name="Occitanie (région administrative)">
<name sortKey="Martel, Jean Claude" sort="Martel, Jean Claude" uniqKey="Martel J" first="Jean-Claude" last="Martel">Jean-Claude Martel</name>
</region>
<name sortKey="Cosi, Cristina" sort="Cosi, Cristina" uniqKey="Cosi C" first="Cristina" last="Cosi">Cristina Cosi</name>
<name sortKey="Marien, Marc R" sort="Marien, Marc R" uniqKey="Marien M" first="Marc R." last="Marien">Marc R. Marien</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000270 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000270 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:04-0345628
   |texte=   Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022